You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2024

Investigational Drug Information for MN-166

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug MN-166?

MN-166 is an investigational drug.

There have been 13 clinical trials for MN-166. The most recent clinical trial was a Phase 2 trial, which was initiated on May 28th 2020.

The most common disease conditions in clinical trials are Sclerosis, Motor Neuron Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are MediciNova, National Institute on Alcohol Abuse and Alcoholism (NIAAA), and University of California, Los Angeles.

There are seven hundred and ninety-two US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for MN-166
A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use DisorderUniversity of PennsylvaniaPhase 2
Canadian Adaptive Platform Trial for Long COVIDUniversity Health Network, TorontoPhase 2/Phase 3
Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDSMediciNovaPhase 2

See all MN-166 clinical trials

Clinical Trial Summary for MN-166

Top disease conditions for MN-166
Top clinical trial sponsors for MN-166

See all MN-166 clinical trials

US Patents for MN-166

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MN-166 ⤷  Sign Up Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Sign Up
MN-166 ⤷  Sign Up Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR) ⤷  Sign Up
MN-166 ⤷  Sign Up Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA) ⤷  Sign Up
MN-166 ⤷  Sign Up Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag The Catholic University of America (Washington, DC) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MN-166

Drugname Country Document Number Estimated Expiration Related US Patent
MN-166 Canada CA2961033 2034-09-11 ⤷  Sign Up
MN-166 European Patent Office EP3192791 2034-09-11 ⤷  Sign Up
MN-166 Japan JPWO2016039408 2034-09-11 ⤷  Sign Up
MN-166 World Intellectual Property Organization (WIPO) WO2016039408 2034-09-11 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.